Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Ratner

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Blood|August 31, 2019
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockadeDaniel A Rauch, Kevin C Conlon, Murali Janakiram, et al.
Cancer|November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 StudyLakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Blood|December 22, 2009
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2025
Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancerPatrick M Grierson, Crystal Wolf, Rama Suresh, et al.
JCI Insight|October 4, 2019
HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemiaJingyu Xiang, Daniel A Rauch, Devra D Huey, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2023
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Blood|August 31, 2019
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockadeDaniel A Rauch, Kevin C Conlon, Murali Janakiram, et al.
Cancer|November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 StudyLakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Blood|December 22, 2009
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2025
Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancerPatrick M Grierson, Crystal Wolf, Rama Suresh, et al.
JCI Insight|October 4, 2019
HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemiaJingyu Xiang, Daniel A Rauch, Devra D Huey, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2023
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Pageof 15